Sravan Kumar Emany insider trades: Beam Therapeutics (BEAM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sravan reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | BEAM | ↓ Sell | 6,294 | $27.10 | $171K | Direct | Jan 5, 2026 (5d) |
| Nov 18, 2024 | IRWD | ↓ Sell | 11,001 | $4.08 | $45K | Direct | Nov 20, 2024 (2d) |
| Mar 4, 2024 | IRWD | ↑ Buy | 10,684 | $9.38 | $100K | Direct | Mar 6, 2024 (2d) |
| Sep 15, 2023 | IRWD | ↑ Buy | 36,072 | $8.32 | $300K | Direct | Sep 18, 2023 (3d) |
| Nov 21, 2022 | IRWD | ↓ Sell | 6,578 | $11.56 | $76K | Direct | Nov 23, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BEAM insiders
Open-market trades in the last 12 months
About Sravan Kumar Emany's insider trades
Sravan Kumar Emany is Chief Financial Officer at Beam Therapeutics (BEAM). Since Nov 21, 2022, Sravan has reported 2 open-market purchases worth $400K and 3 sales worth $291K on SEC Form 4. In the last 12 months: 1 sale ($171K).
Their filings also include grants and awards (12 filings), shares withheld for taxes (3 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BEAM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.